How many insider trades does FilingIQ track for MRUS?

FilingIQ tracks 306 Form 4 insider transactions for MRUS (Merus N.V.), covering filings from Jan 2, 2020 onwards. 0 of those were filed in the last 90 days.

Are MRUS insiders net buyers or net sellers?

Across the full Form 4 history for MRUS, 49 transactions (16%) were open-market purchases and 46 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MRUS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MRUS in?

Merus N.V. (MRUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.83B.

MRUS insider trading

Healthcare

Merus N.V. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

306

Last 90 days

Buys / sells

16% / 15%

Market cap

$6.83B

About Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.

Company website: www.merus.nl

MRUS insider activity at a glance

FilingIQ has scored 306 insider transactions for MRUS since Jan 2, 2020. The most recent filing in our index is dated Dec 29, 2025.

Across the full history, 49 open-market purchases and 46 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MRUS insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MRUS trades on FilingIQ Raw filings on SEC EDGAR

Latest MRUS Form 4 filings

Silverman Peter B. COO & GC

S Dec 15, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for MRUS?: FilingIQ tracks 306 Form 4 insider transactions for MRUS (Merus N.V.), covering filings from Jan 2, 2020 onwards. 0 of those were filed in the last 90 days.
Are MRUS insiders net buyers or net sellers?: Across the full Form 4 history for MRUS, 49 transactions (16%) were open-market purchases and 46 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MRUS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MRUS in?: Merus N.V. (MRUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.83B.

Methodology & sources

Every MRUS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.